Investment Strategically Boosted by Bain Capital, Kohlberg, and Mubadala for PCI Pharma
In a significant move for the pharmaceutical industry, PCI Pharma Services, a global leader in contract development and manufacturing organisation (CDMO), has secured a strategic investment co-led by Bain Capital and Kohlberg. The investment also includes significant reinvestment from Mubadala Investment Company and continued support from Partners Group [1][2][4].
Matt Jennings, Chairman of PCI and an Operating Partner of Kohlberg, expressed his delight at Bain Capital's joining PCI's investor base. Devin O'Reilly, Partner at Bain Capital, shared the excitement, expressing his eagerness to leverage industry expertise and the collaboration of Bain Capital's global healthcare team to support PCI's mission to drive innovation in advanced pharmaceutical services.
Andrew Kaplan and Christina Dix, Partners at Bain Capital, have been instrumental in PCI's transformation into a leading global CDMO over the last five years. They are thrilled to partner with Bain Capital for future investments. Chris Anderson, Senior Partner of Kohlberg, reinvested in PCI due to deep conviction in the company's mission, leadership, and long-term potential, and is delighted to welcome Bain Capital as a partner.
PCI's CEO, Salim Haffar, expressed gratitude for the ongoing support of existing investors and welcomed Bain Capital's involvement. He highlighted that the collaboration aims to accelerate PCI's growth, strengthen customer service, and enable clients to bring biopharmaceutical therapies to market.
The legal counsel for the transaction included Paul, Weiss for PCI and Kohlberg, Kirkland & Ellis for Bain Capital, and Skadden, Arps for Mubadala. Morgan Stanley and BofA Securities advised Bain Capital, and Citi provided financial advisory services to Mubadala. Jefferies served as the lead financial advisor to PCI, with Moelis & Company as co-advisor [1][2].
Based in Philadelphia, PCI offers integrated drug development, manufacturing, and packaging services. With over 450 successful product launches in the last five years and more than 50 years of experience, PCI has established itself as the partner of choice for customers [1]. The company plans to focus on expanding its service offerings and global presence, including enhancements to its sterile fill-finish capabilities and high-potent manufacturing capacity.
Mina Hamoodi, Head of Healthcare at Mubadala, looks forward to supporting PCI and the new ownership group in driving the company into its next phase of growth. Sujit John, Managing Director, Private Equity Health & Life Vertical, Partners Group, acknowledges PCI's market position, reputation, and world-class capabilities, positioning the company as a key player in the pharmaceutical industry.
This strategic investment is expected to support PCI's growth, commercial, clinical trial services, and development and manufacturing businesses [4]. The partnership is set to bring about a new era of innovation and growth for PCI Pharma Services.
[1] PCI Pharma Services Press Release, "PCI Pharma Services Secures Strategic Investment Co-led by Bain Capital and Kohlberg", 2022. [2] BusinessWire, "PCI Pharma Services Secures Strategic Investment Co-led by Bain Capital and Kohlberg", 2022. [4] PR Newswire, "PCI Pharma Services Announces Strategic Investment Co-led by Bain Capital and Kohlberg", 2022.
The strategic investment in PCI Pharma Services, co-led by Bain Capital and Kohlberg, signifies a significant move in the private equity realm, with a focus on the pharmaceutical industry and expanding the business through finance and investing. Devin O'Reilly, Partner at Bain Capital, is excited about leveraging industry expertise from Bain Capital's global healthcare team to support PCI's mission in driving innovation in advanced pharmaceutical services.
